AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

North America HIV Drugs Market: Trends, Share, Size, Growth, Opportunity and Forecast (2019-2024) - ResearchAndMarkets.com

January 2, 2020 GMT

DUBLIN--(BUSINESS WIRE)--Jan 2, 2020--

The “North America HIV Drugs Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024” report has been added to ResearchAndMarkets.com’s offering.

The North American HIV drugs market reached a value of US$ 9.8 Billion in 2018.

This report provides a deep insight into the North America HIV drugs market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.

The North American HIV drugs market is currently being driven by several factors:

The region currently represents one of the strongest economies leading to a well-established healthcare system. This acts as one of the key factors which is fostering the growth of the HIV drugs market in the region. In addition to this, the US and Canadian governments are consistently extending their helping-hand by investing funds on the research and development of safer and potent HIV drugs.

Moreover, higher diagnosis and treatment rate coupled with a surge in the adoption of advanced treatments act as another factor which is facilitating the growth of the HIV drugs market in North America.

Apart from this, Antiretroviral drugs have played a major role in improving survival rates and the quality of life of HIV patients. These drugs help the immune system to keep the levels of the virus to a minimum level and prevent infections, leading to the prolonged life expectancy in patients. Antiretrovirals, when taken in the right combination can result in immune reconstitution, restore health, and prevent the development of AIDS and AIDS-related conditions.

The progressive reduction in mortality and gains in the life expectancy are also a result of the improvements in therapy over the past few years. Additionally, antiretroviral drugs help in reducing the risk of HIV transmission. HIV treatment helps in reducing the level of the virus in the blood and other bodily fluids such as semen and vaginal and rectal fluids to imperceptible levels. It also helps in controlling the replication of the virus in the body.

Key Questions Answered

Report Coverage

Key Topics Covered

1 Preface

2 Scope & Methodology

3 Executive Summary

4 Introduction

4.1 Overview

4.2 Key Industry Trends

5 Global HIV Drugs Market

5.1 Market Performance

5.2 Market Breakup by Drug Class

5.3 Market Breakup by Distribution Channel

5.4 Market Breakup by Region

5.5 Market Forecast

6 North America HIV Drugs Market

6.1 Market Performance

6.2 Market Forecast

7 North America HIV Drugs Market: Breakup by Drug Class

7.1 Nucleoside Reverse Transcriptase Inhibitors

7.2 Multi-Class Combination Products

7.3 Protease Inhibitors

7.4 HIV Integrase Strand Transfer Inhibitors

7.5 Non-Nucleoside Reverse Transcriptase Inhibitors

7.6 Entry Inhibitors - CCR5 Co-Receptor Antagonist

7.7 Others

8 North America HIV Drugs Market: Breakup by Distribution Channel

8.1 Hospital Pharmacies

8.2 Retail Pharmacies

8.3 Online Pharmacies

8.4 Others

9 North America HIV Drugs Market: Breakup by Country

9.1 United States

9.1.1 Historical Market Trends

9.1.2 Market Breakup by Drug Class

9.1.3 Market Breakup by Distribution Channel

9.1.4 Market Forecast

9.2 Canada

9.2.1 Historical Market Trends

9.2.2 Market Breakup by Drug Class

9.2.3 Market Breakup by Distribution Channel

9.2.4 Market Forecast

10 SWOT Analysis

10.1 Overview

10.2 Strengths

10.3 Weaknesses

10.4 Opportunities

10.5 Threats

11 Value Chain Analysis

11.1 Overview

11.2 Research and Development

11.3 Raw Material Procurement

11.4 Manufacturing

11.5 Marketing

11.6 Distribution

11.7 End-Use

12 Porter’s Five Forces Analysis

12.1 Overview

12.2 Bargaining Power of Buyers

12.3 Bargaining Power of Suppliers

12.4 Degree of Rivalry

12.5 Threat of New Entrants

12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

14.1 Market Structure

14.2 Key Players

14.3 Profiles of Key Players

For more information about this report visit https://www.researchandmarkets.com/r/yykaof

View source version on businesswire.com:https://www.businesswire.com/news/home/20200102005357/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2020.

PUB: 01/02/2020 10:13 AM/DISC: 01/02/2020 10:12 AM

http://www.businesswire.com/news/home/20200102005357/en